Rare sugars like D-allulose, D-tagatose, and D-sorbose significantly boosted GLP-1 secretion and suppressed food intake in ...

Contrave and Wegovy are both weight loss medications. Learn about their effectiveness, side effects, costs, and which ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

A randomized clinical trial compared the effects of 4:3 intermittent fasting versus daily caloric restriction on weight loss when combined with comprehensive behavioral support in adults with ...

A new study conducted by researchers at USC’s Keck School of Medicine explored a popular artificial sweetener – sucralose. ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

A study by USC reveals that sucralose, a common artificial sweetener, alters brain activity in regions controlling hunger.

Trader Joe’s hummus snack pack with pita chips is a convenient, high-protein snack. A high-protein snack can fuel your body ...

An estimated 15 million Americans are currently taking semaglutide weight loss drugs, which are proven to impact alcohol ...

Use of cutting-edge weight-loss drugs like Ozempic and Zepbound has increased dramatically among people with type 1 diabetes, raising safety concerns among experts, a new study says.

Structure Therapeutics Inc.’s GPCR share price has dipped by 12.27%, which has investors questioning if this is right time to buy.